Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Persistent selling mars indices
Fri, 15 Oct Closing

Sustained selling activity across index heavyweights throughout the trading session today ensured that Indian indices closed deep into the red. After opening in the negative in the early hours of trade, the indices steadily lost ground and kept racking up losses as the day progressed. While the BSE Sensex closed lower by around 373 points (down 2%), the NSE Nifty lost around 115 points (down 2%). The BSE Midcap and the BSE Smallcap also lost around 1% each. Losses were largely seen in IT and auto stocks.

As regards global markets, Asian indices closed mixed today while European indices have also opened on a mixed note. The rupee was trading at Rs 44.06 to the dollar at the time of writing.

Auto stocks closed weak today and the key losers here included Tata Motors, Hero Honda and M&M. As per a leading business daily, Tata Motors saw a strong growth in global sales in September. Sales rose by 19% on the back of robust demand for both commercial and passenger vehicles. Luxury brands such as Jaguar and Land Rover also did very well during the month. While sales of luxury sedan Jaguar grew by 10% to 4,861 units, Land Rover sales were higher by 19% at 14,667 units. Meanwhile, total passenger vehicle sales witnessed a growth of 21% YoY during the month, while sales of commercial vehicles stood at 18%. It must be noted that Tata Motors did very well in 1QFY11 wherein consolidated sales grew by a robust 64% YoY on the back of higher volumes and realisations. Operating margins on a consolidated basis had also jumped from 3.6% in 1QFY10 to as much as 14.6% in 1QFY11.

As per a leading business daily, Piramal Healthcare expects revenues to fall by Rs 12-13 bn in FY11. This is not surprising given that the company has sold its domestic formulations business (nearly 50% of its total sales) to Abbott Laboratories for US$ 3.72 bn. Therefore, in FY11, sales of the hived off business will be reflected in the numbers for only 5 months. It must be noted that with the proceeds from the sale Piramal Healthcare intends to repay debt, pay capital gains tax and reward shareholders in the form of a special dividend. The management has also indicated its intention to venture into areas beyond healthcare although the exact details of the same have not been divulged. The stock closed lower today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Persistent selling mars indices". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.